Vanguard Global Advisers
RVMD icon

Vanguard Global Advisers’s Revolution Medicines RVMD Stock Holding History

Vanguard Global Advisers’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Buy
82,088
+3,606
+5% +$527K 0.01% 590
2026
Q1 		$7.63M Buy
+78,482
New +$7.92M ﹤0.01% 662

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Global Advisers's RVMD Position: Q2 2026 in Review

Vanguard Global Advisers increased its Revolution Medicines (RVMD) stake by 4.6% in Q2 2026, buying an estimated $527K and bringing the position to 82,088 shares worth $15.4M. The position accounts for 0.01% of the portfolio, ranked #590.

Vanguard Global Advisers first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Vanguard Global Advisers held 82,088 shares of Revolution Medicines worth $15.4M as of Q2 2026.
  • Vanguard Global Advisers bought 3,606 Revolution Medicines shares in Q2 2026, an estimated $527K.
  • Revolution Medicines made up 0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #590 holding.
  • Vanguard Global Advisers first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.